IrelandIreland

Label change for Elan's MS-drug permits safer use

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the JC-virus marks a higher risk of developing progressive multifocal leukoencephalopathy (PML). A new label identifies anti-JCV antibody status as a third risk factor for developing PML. Tysabri (natalizumab) increases the risk of PML, an opportunistic viral infection of the brain which in most cases leads to death or severe disability. With the label update, which the companies say was inspired by their own research, physicians now have others factor at hand when weighing the risks and benefits of applying Tysabri. “We welcome the inclusion of PML risk stratification in the U.S. label as it significantly supports our aim to provide the information patients and physicians need to make a more informed treatment decision,” said Kelly Martin, CEO of Elan. Tysabri is approved in about 65 countries and results in a 68% relative reduction in the annualised relapse rate when compared with placebo, according to studies conducted by Elan.

IrelandIreland

14.10.2009

Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds...

IrelandIreland

19.09.2009

Dublin – The Republic of Ireland has amended its patent law to bring it into line with the rest of Europe and make its domestic patenting system more straightforward. The government said increased levels of research in Ireland in...

IrelandIreland

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the...

IrelandIreland

12.07.2009

Dublin – Ireland is focussing on expanding productivity in the upstream processing of biological drugs. Science Minister Conor Lenihan has announced EUR2.3m in funding for the next 3 years aimed at delivering more efficient and...

IrelandIreland

07.07.2009

Dublin/New Brunswick – Pharma giant Johnson &Johnson will buy all assets of Irish Elan Pharmaceuticals’ Alzheimer’s Immunotherapy Programme (AIP) through a newly formed company. The new company will pay $1 billion for an 18.4%...

IrelandIreland

17.06.2009

Dublin – Trinity College of Dublin's Institute of Molecular Medicine has opened Ireland´s first next generation DNA sequencing facility. The platform, built upon the current market-leading “Illumina Genome Analyzer II“ platform,...

IrelandIreland

14.06.2009

Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the...

IrelandIreland

22.04.2009

Dublin – Ireland fears growing rates of resistant pneumococcus in the country's hospitals. A recent report by the Health Protection Surveillance Centre (HSPC) shows that 32% of 124 clinical isolates tested were non-susceptible to...

IrelandIreland

31.10.2008

Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has...

IrelandIreland

14.08.2008

Dublin/Zurich – Analyst Ian Hunter of Goodbody Stockbrokers has maintained his “add” rating on Irish Elan Corp Plc. The fair value for the pharma combine has been raised from EUR18 to EUR19. The analyst says that the company has...

Displaying results 21 to 30 out of 49

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/2/article/label-change-for-elans-ms-drug-permits-safer-use.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper